the FDA’s approval of remdesivir falls on the heels of data form the fourth and largest trial of the drug, and that trial showed no benefit. The data comes from the World Health Organization’s massive Solidarity trial, which set up an international network of trials enrolling nearly 12,000 patients at 500 sites in over 30 countries, testing multiple repurposed therapeutics. Remdesivir was initially developed over a decade ago as a potential treatment for hepatitis C and RSV (respiratory syncytial virus). It has also been tested against Ebola but was beat out by other treatments. According to preliminary results from the Solidarity trial—reported online last week ahead of its planned publication in the New England Journal of Medicine—remdesivir was given to 2,743 patients, and their outcomes were compared with those of 2,708 patients given standard treatments. Between the two groups, WHO found that remdesivir did not reduce mortality. It also did not change how many patients progressed to needing mechanical ventilation, nor did it change the proportion of patients discharged after seven days of hospitalization.